<DOC>
	<DOCNO>NCT01988116</DOCNO>
	<brief_summary>The purpose study learn treatment vitamin D affect iron metabolism blood level two hormone control iron level , hepcidin hemojuvelin people chronic kidney disease ( CKD ) . Iron essential mineral major component protein carry oxygen blood . Problems iron metabolism lead low blood level ( anemia ) , commonly happen people CKD . New research last decade uncover new hormone call ` hepcidin ' , make liver release blood . Hepcidin control much iron blood prevent absorption iron food . Blood level hepcidin C find high people CKD , recent small study people normal kidney function show treatment vitamin D decrease hepcidin level . Another protein , know ` hemojuvelin ' , recently discover also think control amount iron blood . The relationship vitamin D hemojuvelin never study . In study , investigator would like examine effect vitamin D iron metabolism blood level hepcidin C hemojuvelin individual CKD .</brief_summary>
	<brief_title>Effects Vitamin D Replacement Hormones Regulating Iron Metabolism Individuals With Chronic Kidney Disease</brief_title>
	<detailed_description>Iron homeostasis tightly regulate human . Iron mostly recycle hemoglobin , myoglobin enzyme . Since human lack capacity excrete excess iron , must intricately regulate site absorption duodenum proximal jejunum . In last decade , hepcidin emerge master regulator iron homeostasis . It decrease iron absorption gut mucosa limit transport enterocyte across basolateral membrane circulation . It down-regulating synthesis promote internalization basolateral membrane protein ` Ferroportin ' , know cellular iron exporter . Vitamin D hypothesize exert significant independent effect iron metabolism . In CKD population , low vitamin-D level independently correlate severity anemia . Hepcidin C level find elevate CKD population . Mechanisms underlie effect vitamin D iron homeostasis potentially include vitamin D induce expression erythropoietin receptor , increase proliferation erythroid precursor , reduction hepcidin C level due reduction IL-6 anti-inflammatory effect vitamin D. More recently , study reveal direct relationship vitamin D replacement sustain fall hepcidin C level . The group researcher find relationship due direct effect vitamin D hepcidin expression . Hemojuvelin ( HJV ) protein encode HFE2 gene find membrane bind soluble form ( sHJV ) human . Mutations HJV gene responsible Juvenile Hemochromatosis . It upstream regulator hepcidin transcription appear essential hepcidin expression hepatocytes important role play iron homeostasis . Recently , assay become available measure sHJV level serum . Although , know hepcidin play central role iron homeostasis recent study give u insight role hemojuvelin vitamin D play iron metabolism , date , study examine effect vitamin D replacement hepcidin , hemojuvelin level iron metabolism individual CKD . Hypothesis 1 : Treatment activate vitamin D analog individual CKD result statistically significant fall hepcidin C level compare individual provide placebo . Hypothesis 2 : Treatment activate vitamin D analog result decrease level soluble hemojuvelin individual chronic kidney disease . Hypothesis 3 : Vitamin D replacement individual CKD result improve iron parameter compare placebo .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Hepcidins</mesh_term>
	<criteria>Patients mild moderate CKD ( eGFR 15 60 ml/min/1.73 m2 ) estimate CKDEPI ( Chronic Kidney Disease Epidemiology Collaboration ) formula . Subjects currently receive active vitamin D analog therapy history recent ( &lt; 3 month ) use . Subjects currently receive nutritional vitamin D ( cholecalciferol ergocalciferol ) dosages great 2000 IU/day . Subjects receive erythropoiesis stimulate agent . Subjects receive intravenous iron therapy . Subjects receive oral iron therapy start within 3 month prior recruitment . Subjects severe anemia define Hb &lt; 8.0 g/dL male Hb &lt; 7.0 g/dL female . Subjects iron deficiency anemia define serum ferritin &lt; 100ng/ml Transferring Saturation &lt; 20 % . Pregnancy lactation . Subjects hypercalcemia define serum calcium level &gt; 10.0 mg/dL . Subjects serum phosphorus concentration &gt; 4.5 mg/dL . Subjects acute kidney injury rapidly decline GFR . Subjects receive form renal replacement therapy include hemodialysis , peritoneal dialysis , patient renal transplant . Subjects focus active inflammation infection determine clinically .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Anemia chronic disease</keyword>
	<keyword>Iron Metabolism</keyword>
	<keyword>Iron Homeostasis</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Calcitriol</keyword>
	<keyword>hemojuvelin</keyword>
	<keyword>hepcidin</keyword>
	<keyword>anemia</keyword>
	<keyword>ferroportin</keyword>
</DOC>